Combination therapy with device for metastatic pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced pancreatic cancer that has spread to other organs.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are 18 years or older; if you are 80 or older, your doctor will check your overall health closely.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- Your blood counts, kidney and liver function are within certain limits.
- You have not had gemcitabine or nab-paclitaxel chemotherapy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a combination of immunotherapy (penpulimab), a targeted therapy (anlotinib), and two chemotherapy drugs (nab-paclitaxel and gemcitabine) as a first treatment for pancreatic cancer that has spread. It aims to see if this new combination works better than standard care.
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.